Treatment of Pyelonephritis in Patients with Cirrhosis

Initial Antibiotic Selection

• The European Association for the Study of the Liver recommends starting empirical broad-spectrum antibiotics immediately upon suspicion of pyelonephritis in cirrhotic patients, as they are highly susceptible to rapid clinical deterioration from bacterial infections 1, 2

Critical Monitoring Requirements

• The American Association for the Study of Liver Diseases suggests obtaining blood and urine cultures before initiating antibiotics to guide subsequent therapy in cirrhotic patients with pyelonephritis 1

Albumin Administration

• The European Association for the Study of the Liver recommends considering albumin infusion (1.5 g/kg within 6 hours, followed by 1 g/kg on day 3) if the patient develops signs of renal impairment or sepsis, as this intervention has been shown to reduce mortality in cirrhotic patients with severe infections 3

Important Caveats

• The Infectious Diseases Society of America advises avoiding fluoroquinolones in patients already on quinolone prophylaxis for SBP, as this increases risk of resistant organisms 5
• The European Association for the Study of the Liver recommends being vigilant for fluoroquinolone-associated tendon complications, particularly in patients with renal impairment, and discontinue at first sign of tendon pain 5

Addressing Underlying Cirrhosis Complications

• The American Association for the Study of Liver Diseases suggests managing ascites appropriately with combination spironolactone and furosemide if present, as fluid overload can complicate infection management 7
• The European Association for the Study of the Liver recommends assessing for liver transplant candidacy, as severe infections in cirrhotic patients indicate advanced disease with poor prognosis 8, 3